Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients at a Tertiary Care Hospital of Karachi.

NCT02050529 is registered in ClinicalTrials.gov with Dow University of Health Sciences as lead sponsor.

NCT NCT02050529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02050529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients at a Tertiary Care Hospital of Karachi.
Lead sponsor
Dow University of Health Sciences
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
March 31, 2015
Enrollment
190 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hydralazine adverse reaction, hypertension, pregnancy induced, pre-eclampsia, pre-eclampsia superimposed pre-existing hypertension